SCHEMBL2599757

SCHEMBL2599757

Cc1ccc(Cl)c2c1c(C=O)cn2C(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.32
LMNA P02545 1/20 0.31
POLB P06746 2/20 0.30
TDP1 Q9NUW8 2/20 0.30
NSD2 O96028 1/20 0.30
PKM P14618 1/20 0.30
APEX1 P27695 1/20 0.30
CASP3 P42574 1/20 0.30
RECQL P46063 1/20 0.30
CASP6 P55212 1/20 0.30
CTDSP1 Q9GZU7 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
GAA P10253 1/20 0.30
RAB9A P51151 1/20 0.30
CACNA1B Q00975 1/20 0.30
APBA1 Q02410 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599761 0.89 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2POLBTDP1MEN1
SCHEMBL14689705 0.73 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2LMNAPOLBTDP1
SCHEMBL12182595 0.70 TDP1 (0.34) ALDH1A1SMN1; SMN2TDP1
SCHEMBL14519092 0.69 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2TSHRLMNATDP1
SCHEMBL2599740 0.69 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2LMNAPOLBTDP1
SCHEMBL2599821 0.68 TRIM24 (0.42) ALDH1A1SMN1; SMN2TSHRMEN1RAB9A
SCHEMBL2599755 0.67 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2
SCHEMBL2599736 0.67 ERN1 (0.40) ALDH1A1SMN1; SMN2LMNAPOLBTDP1
SCHEMBL5259766 0.65 KDR (0.37) KMT2A
SCHEMBL672433 0.64 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571356-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2013-03-27 EP disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS SSTR5, SSTR2, SSTR1 ALDH1A1 1103/4885SMN1; SMN2 2690/4885TSHR 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.